


derivative comprising:



As shown above, the claimed quinoxaline has a phenylene skeleton (emphasis added for illustrative purposes only).

In contrast, the Examiner cites to Figs. 24 and 25 in Li as allegedly disclosing the claimed quinoxaline derivative. However, as illustrated, the compound in Figs. 24 and 25 in Li (see attached circled illustrations) has a pyridine skeleton which is different than the phenylene skeleton (circled above) of the claims of the present application. Therefore, Li does not disclose or suggest the claimed invention, and Claims 1-4 and 9-17 are patentable over Li.

Accordingly, it is respectfully requested that this rejection be withdrawn.

#### Information Disclosure Statement

Applicant filed an information disclosure statement (IDS) with a 1449 form on January 10, 2008, with the RCE. The Office Action of April 4, 2008 states that Applicant's submission filed on

January 10, 2008 has been entered. However, Applicants did not receive an initialed 1449 form for the January 10, 2008 IDS. It is respectfully requested that the Examiner issue an initialed 1449 form for this IDS.

Conclusion

It is respectfully submitted that the present application is in a condition for allowance and should be allowed.

If any fee should be due for this response, please charge our deposit account 50/1039.

Favorable reconsideration is earnestly solicited.

Date: July 7, 2008

Respectfully submitted,

/Mark J. Murphy/

Mark J. Murphy

Registration No. 34,225

COOK ALEX LTD.  
200 West Adams Street  
Suite 2850  
Chicago, Illinois 60606  
(312) 236-8500

Customer No. 26568




FIG. 24

